Ayele Wondimu, Mulugeta Afework, Desta Alem, Rabito Felicia A
School of Public Health, Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.
Department of Public Health, Mekelle University, Mekelle, Ethiopia.
BMC Public Health. 2015 Aug 27;15:826. doi: 10.1186/s12889-015-2176-5.
Ethiopia has been providing free Antiretroviral Treatment (ART) since 2005 for HIV/AIDS patients. ART improves survival time and quality of life of HIV patients but ART treatment outcomes might be affected by several factors. However, factors affecting treatment outcomes are poorly understood in Ethiopia. Hence, this study assesses treatment outcomes and its determinants for HIV patients on ART in selected health facilities of Kembata and Hadiya zones.
A retrospective cohort study was conducted on 730 adult HIV/AIDS patients who enrolled antiretroviral therapy from 2007 to 2011 in four selected health facilities of Kembata and Hadiya zones of Southern Ethiopia. Study subjects were sampled from the health facilities based on population proportion to size. Data was abstracted using data extraction format from medical records. Kaplan-Meier survival function was used to estimate survival probability. Cox proportional hazards regression model was used to identify factors associated with time to death.
Median age of patients was 32.4 years with Inter Quartile Range (IQR) [15, 65]. The female to male ratio of the study participants' was 1.4:1. Median CD4 count significantly increased during the last four consecutive years of follow up. A total of 92 (12.6%) patients died, 106(14.5%) were lost to follow-up, and 109(15%) were transferred out. Sixty three (68%) deaths occurred in the first 6 months of treatment. The median survival time was 25 months with IQR [9, 43]. After adjustment for confounders, WHO clinical stage IV [HR 2.42; 95% CI, 1.19, 5.86], baseline CD4 lymphocyte counts of 201 cell/mm(3) and 350 cell/mm(3) [HR 0.20; 95 % CI; 0.09-0.43], poor regimen adherence [HR 2.70 95% CI: 1.4096, 5.20], baseline hemoglobin level of 10 gm/dl and above [HR 0.23; 95% CI: 0.14, 0.37] and baseline functional status of bedridden [HR 3.40; 95% CI: 1.61, 7.21] were associated with five year survival of HIV patients on ART.
All people living with HIV/AIDS should initiate ART as early as possible. Initiation of ART at the early stages of the disease, before deterioration of the functional status of the patients and before the reduction of CD4 counts and hemoglobin levels with an intensified health education on adherence to ART regimen is recommended.
自2005年以来,埃塞俄比亚一直在为艾滋病毒/艾滋病患者提供免费抗逆转录病毒治疗(ART)。抗逆转录病毒治疗可提高艾滋病毒患者的生存时间和生活质量,但治疗结果可能受到多种因素的影响。然而,在埃塞俄比亚,影响治疗结果的因素尚不清楚。因此,本研究评估了肯巴塔和哈迪亚地区选定医疗机构中接受抗逆转录病毒治疗的艾滋病毒患者的治疗结果及其决定因素。
对2007年至2011年在埃塞俄比亚南部肯巴塔和哈迪亚地区四个选定医疗机构登记接受抗逆转录病毒治疗的730名成年艾滋病毒/艾滋病患者进行了一项回顾性队列研究。研究对象根据人口比例从医疗机构中抽样。使用数据提取格式从医疗记录中提取数据。采用Kaplan-Meier生存函数估计生存概率。使用Cox比例风险回归模型确定与死亡时间相关的因素。
患者的中位年龄为32.4岁,四分位间距(IQR)为[15,65]。研究参与者的男女比例为1.4:1。在连续四年的随访中,中位CD4细胞计数显著增加。共有92名(12.6%)患者死亡,106名(14.5%)失访,109名(15%)转出。63例(68%)死亡发生在治疗的前6个月。中位生存时间为2年5个月,IQR为[9,43]。在对混杂因素进行调整后,世界卫生组织临床分期IV期[风险比(HR)2.42;95%置信区间(CI),1.19,5.86]、基线CD4淋巴细胞计数为201个细胞/mm³和350个细胞/mm³[HR 0.20;95%CI;0.09 - 0.43]、治疗方案依从性差[HR 2.70 95%CI:1.4096,5.20]、基线血红蛋白水平为10 gm/dl及以上[HR 0.23;95%CI:0.14,0.37]以及基线功能状态为卧床不起[HR 3.40;95%CI:1.61,7.21]与接受抗逆转录病毒治疗的艾滋病毒患者的五年生存率相关。
所有艾滋病毒/艾滋病感染者应尽早开始抗逆转录病毒治疗。建议在疾病早期、患者功能状态恶化之前、CD4细胞计数和血红蛋白水平降低之前开始抗逆转录病毒治疗,并加强关于坚持抗逆转录病毒治疗方案的健康教育。